The worldwide infection rate for HIV-1 is estimated to be 14,000 per day, but only now, more
than 20 years into the epidemic, are the immediate events between exposure to infectious …

Summary 25 years after the first HIV/AIDS cases emerged in 1981, the disease continues to
spread worldwide, with about 15 000 new infections every day. Although highly active …

Background We wished to determine the safety and anti–human immunodeficiency virus
(HIV) type 1 activity of single doses of TNX-355, a humanized IgG4 anti-CD4 monoclonal …

Most of HIV-1 infections are acquired through sexual contact. In the absence of a preventive
vaccine, the development of topical microbicides that can block infection at the mucosal …

The HIV infection is responsible for the most devastating global pandemic of the last century.
More than 39 million people have died of HIV/AIDS since 1981. The development of the …

Ibalizumab is a humanized, anti-CD4 monoclonal antibody. It potently blocks HIV-1 infection
and targets an epitope in the second domain of CD4 without interfering with immune …

Objective: To evaluate the anti-HIV-1 activity of the cyclotriazadisulfonamide CADA against
primary isolates in vitro and the combination of CADA with approved anti-HIV drugs for …

The majority of currently available agents for the treatment of HIV-1 infection act by targeting
one of several intracellular steps in the viral life cycle. Despite improvements in efficacy and …

Current therapeutic intervention in HIV infection relies upon 20 different drugs. Despite the
impressive efficacy shown by these drugs, we are confronted with an unexpected frequency …

Monoclonal antibodies represent a major and increasingly important category of
biotechnology products for the treatment of human diseases. The state‐of‐the‐art of …